The effect of palivizumab prophylaxis on respiratory syncytial virus-associated hospitalizations in infants with congenital diaphragmatic hernia

We read with great interest the article authored by Resch et  al.1 [1] that reported a moderate risk of respiratory syncytial virus (RSV)-associated hospitalizations in infants with congenital diaphragmatic hernia (CDH) and that palivizumab prophylaxis resulted in a nonsignificant reduction in the number of RSV-associated hospitalizations. Although this is a n important finding having clinical implications, this study has some limitations, and we would like to make some comments on this article.

Source: Pediatrics and Neonatology - March 16, 2018 Category: Perinatology & Neonatology Authors: Pei-Lan Shao Tags: Editorial Source Type: research